From disease-specific targets to focused therapeutics

Alethia Biotherapeutics is developing innovative therapeutic approaches in areas of unmet medical needs. Alethia is currently focusing on ovarian cancer, on severe bone loss that occurs in metastatic cancer, and on metastatic breast cancer, three indications for which there are very few therapeutic options. Alethia capitalizes on its capacity to identify and validate disease-specific targets for the development of highly focused therapeutics.

News


March 31, 2008

GO Capital and BDC Venture Capital invest in Alethia Biotherapeutics


June 8, 2008

Alethia Biotherapeutics announces the nominations of Mr. Luc Mainville, Ms. Ela Borenstein and, Dr. Louise Proulx to its board of directors


June 14, 2008

Alethia Biotherapeutics is moving to a modern new facility 


New address:

141, ave. du Président-Kennedy

Suite SB-5100

Montréal, Québec H2X 1Y4


More news

Events


May 4-6, 2008

Alethia to present data on its ovarian cancer program at the 4th Canadian Conference on Ovarian Cancer Research, Montréal, QC


Mario Filion and Gilles Tremblay will be in attendance.


June 17-20, 2008

Alethia Biotherapeutics Inc. to be part of the Quebec delegation at BIO 2008, San Diego, USA.


Yves Cornellier, Mario Filion and Gilles Tremblay will be in attendance.


Details

Copyright © 2002-2008 Alethia Biotherapeutics Inc. All rights reserved.

Best viewed with Firefox, Internet Explorer 7 and Safari